Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago-Reference-Cited by-同舟云学术

Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

Published:2022-02-28 Issue:3 Volume:12 Page:761-770
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Elberdín Laida,Fernández-Torres Rosa M.,Paradela Sabela,Mateos María,Blanco Eva,Balboa-Barreiro Vanesa,Gómez-Besteiro María I.,Outeda Maria,Martín-Herranz Isabel,Fonseca Eduardo

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00693-2.pdf

Reference11 articles.

1. Baniandrés O, Pulido A, Silvente C, Suárez R, Lázaro P. Evolución clínica de los pacientes psoriásicos tratados con efalizumab al suspender el fármaco. Actas Dermosifiliogr. 2010;101:423–9.

2. Puig L, Carrascosa JM, Daudén E, Sulleiro S, Guisado C. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J Dermatolog Treat. 2020;31:344–51.

3. No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29:460–6.

4. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–58.

5. Elberdín L, Fernández-Torres R, Paradela S, et al. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital. J Dermatolog Treat. 2019;31(7):698–701.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis;Biomolecules;2024-05-03

2. PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis;Genes;2024-03-17

3. Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis;Clinical and Translational Science;2023-12-19

4. Psoriasis: Striving for Potential Biomarkers;ASSAY and Drug Development Technologies;2023-09-01

5. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25